Stable bronchiectasis
Conditions
Interventions
treatment group:Qingfei drainage Tan prescription (the drug is composed of asparagus, raw astragalus, platycodon, Houttuyniae, golden buckwheat, etc.), 1 bag at a time, 2 times a day, early and late b
control group:Qingfehuatan decoction simulator (the drug is composed of asparagus root, raw astragalus, platycodon, Htuynia, golden buckwheat, etc.), 1 bag at a time, 2 times a day, early and late boi
Sponsors
China-japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) meeting the clinical diagnosis of bronchiectasis; (2) TCM syndrome differentiation is phlegm-heat obstructing lung syndrome; (3) Age 18-70 years old (including 18 and 70 years old), gender is not limited; (4) Voluntarily participate in this clinical trial and sign a written informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who do not meet the above Western medicine diagnosis and TCM syndrome differentiation criteria, with hemoptysis as the main manifestation of dry bronchiectasis; (2) Patients who had disease changes within 4 weeks before enrollment; (3) Other types of respiratory infections include acute rhinitis, sinusitis, tracheo-bronchitis, and pneumonia; (4) accompanied by chronic respiratory diseases (such as COPD, interstitial pneumonia, pulmonary heart disease), severe kidney disease, liver disease, blood system diseases, nervous system and neuromuscular diseases, immune suppression (including immunosuppressants or HIV infection caused by immune dysfunction); (5) Women who are pregnant or plan to become pregnant in the next 3 months, breastfeeding women; A woman of childbearing age who is unable or unwilling to use adequate contraception or whose spouse is unwilling to use contraception during the trial period or within 1 month after the last dose; (6) Unable or unwilling to cooperate with clinical trials due to other diseases; (7) Suspected or confirmed history of alcohol or drug abuse; (8) Have participated in other clinical trials or are participating in other drug clinical trials within the last 3 months; (9) Those who are not considered suitable by the doctor to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour sputum volume;TCM syndrome score; | — |
Secondary
| Measure | Time frame |
|---|---|
| cough evaluation test;chronic obstructive pulmonary disease assessment test; | — |
Countries
China
Contacts
Public Contactxinyang shu
TCM Lung Disease department,China-Japan Friendship Hospital
Outcome results
None listed